Piper Sandler previously had a neutral for Aligos Therapeutics Inc. The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 ...
The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...
On 3 rd June, financial analyst Geoffrey Porges of SVB Leerink predicted that remdesivir would deliver revenues approaching $2 billion in 2020, rising to $7.7 billion by 2022. These figures are ...
J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price ...
Nkarta, Inc. (NASDAQ:NKTX – Free Report) – Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Nkarta in a research report issued on Wednesday ...
Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS. Get ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed last Friday at $2.98. Discover the latest stocks ...
Silicon Valley Bank (SVB) was a subsidiary of Silicon Valley Bank Financial Group (SVBFG), a bank holding company, financial holding company, and financial services company. Silicon Valley Bank ...
Leerink Partners heeft maandag het koersdoel voor Lava Therapeutics NV (NASDAQ:LVTX) aanzienlijk verlaagd naar $ 1,00 van het eerdere doel van $ 2,00, terwijl het Market Perform advies voor de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback